TY - JOUR
T1 - Reimbursement for continuous glucose monitoring
T2 - A European view
AU - Heinemann, Lutz
AU - Franc, Sylvia
AU - Phillip, Moshe
AU - Battelino, Tadej
AU - Ampudia-Blasco, Francisco Javier
AU - Bolinder, Jan
AU - Diem, Peter
AU - Pickup, John
AU - DeVries, Hans
PY - 2012/11
Y1 - 2012/11
N2 - Different systems for continuous glucose monitoring (CGM) are available on the European market. There is no unlimited reimbursement for CGM use in any European country, but in some countries, reimbursement exists for certain clinical indications. The aim of this commentary is to describe the different reimbursement situations across Europe for this innovative but costly technology, as a prelude to establishing more uniform use. From the perspective of many scientists and clinicians, a number of randomized controlled trials have demonstrated the efficacy of real-time CGM versus self-monitoring of blood glucose, at least for hemoglobin A1c reduction. Nevertheless, according to many health care professionals and potential CGM users, national health services and health insurance organizations are reluctant to reimburse CGM. Imminent technological and manufacturing developments are expected to reduce the day-to-day costs of CGM.
AB - Different systems for continuous glucose monitoring (CGM) are available on the European market. There is no unlimited reimbursement for CGM use in any European country, but in some countries, reimbursement exists for certain clinical indications. The aim of this commentary is to describe the different reimbursement situations across Europe for this innovative but costly technology, as a prelude to establishing more uniform use. From the perspective of many scientists and clinicians, a number of randomized controlled trials have demonstrated the efficacy of real-time CGM versus self-monitoring of blood glucose, at least for hemoglobin A1c reduction. Nevertheless, according to many health care professionals and potential CGM users, national health services and health insurance organizations are reluctant to reimburse CGM. Imminent technological and manufacturing developments are expected to reduce the day-to-day costs of CGM.
KW - Benefit
KW - Continuous glucose monitoring
KW - Economic aspects
KW - Reimbursement
UR - http://www.scopus.com/inward/record.url?scp=84882239804&partnerID=8YFLogxK
U2 - 10.1177/193229681200600631
DO - 10.1177/193229681200600631
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???
C2 - 23294797
AN - SCOPUS:84882239804
SN - 1932-2968
VL - 6
SP - 1498
EP - 1502
JO - Journal of diabetes science and technology
JF - Journal of diabetes science and technology
IS - 6
ER -